By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Allée de la Recherche, 60

Brussels    1070  Belgium
Phone: 32-2-559-9999 Fax: 32-2-559-9900



Company News
UCB SA Terminates $1.53 Billion Sale Of Generic Drug Unit To Buyout Firms 12/17/2014 6:24:18 AM
Illinois-Based Akorn, Inc. (AKN) Eyes $2 Billion UCB SA Unit In Potential Tax Inversion Deal 9/12/2014 6:38:34 AM
UCB SA to Enhance Informatics Environment With Dotmatics' Vortex 8/7/2013 9:42:46 AM
Immunomedics, Inc. (IMMU) and UCB SA Announce Restructuring of Epratuzumab License Agreement for Up to $60 Million 12/28/2011 7:49:24 AM
UCB SA Release; Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures 12/5/2011 12:34:12 PM
UCB SA Pleads Guilty to Illegal Off-Label Marketing of Epilepsy Drug Keppra; to Pay $34.4 Million 6/9/2011 10:24:03 AM
UCB SA Plans EUR250M ($334M) Plant To Meet Cimzia Demand 1/3/2011 11:44:01 AM
Actient Pharmaceuticals LLC Inks Deal with UCB SA for Marketed Drugs with Global Sales of $53M 7/30/2010 7:25:22 AM
UCB SA And Immunomedics, Inc. (IMMU) Release: New Data From EMBLEM(TM) Study Show Pipeline Drug Epratuzumab Provided Significant Efficacy for Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 6/16/2010 8:34:52 AM
UCB SA Subsidiary, Schwarz Pharma, To Pay $22M In False Claims Settlement 4/30/2010 8:17:37 AM